Alvimopan-d7

Alvimopan-d7 (ADL 8-2698-d7) is deuterium labeled Alvimopan. Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively) . Alvimopan can be used for the research of postoperative ileus[1][2][3].

Product Specifications

CAS Number

[1261396-48-8]

Product Name Alternative

ADL 8-2698-d7; LY 246736-d7

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Opioid Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Applications

Cancer-programmed cell death

Field of Research

Neurological Disease; Cancer

Smiles

C[C@]1(C2=CC(O)=CC=C2)[C@H](CN(CC1)C[C@@H](C(NCC(O)=O)=O)C([2H])([2H])C3=C([2H])C([2H])=C([2H])C([2H])=C3[2H])C

Molecular Formula

C25H25D7N2O4

Molecular Weight

431.58

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Bourdonnec BL, et, al. Novel trans-3,4-dimethyl-4- (3-hydroxyphenyl) piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles. Bioorg Med Chem Lett. 2008 Mar 15;18 (6) :2006-12.|[3]Erowele GI, et, al. Alvimopan (Entereg), a Peripherally Acting mu-Opioid Receptor Antagonist For Postoperative Ileus. P T. 2008 Oct;33 (10) :574-83.|[4]Meerveld BG, et, al. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:46-53.